Jefferies Group Research Analysts Reduce Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at Jefferies Group dropped their FY2018 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued on Thursday. Jefferies Group analyst M. Andrews now expects that the firm will post earnings of $0.15 per share for the year, down from their previous estimate of $0.17. Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ FY2019 earnings at $0.93 EPS, FY2020 earnings at $1.34 EPS and FY2021 earnings at $1.42 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, February 15th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.05. The business earned $38.24 million during the quarter, compared to analyst estimates of $39.38 million. Vanda Pharmaceuticals had a negative net margin of 23.07% and a negative return on equity of 16.13%.

“Jefferies Group Research Analysts Reduce Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)” was originally posted by Web Breaking News and is owned by of Web Breaking News. If you are reading this article on another site, it was stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be viewed at http://www.webbreakingnews.com/2017/02/17/jefferies-group-research-analysts-reduce-earnings-estimates-for-vanda-pharmaceuticals-inc-vnda.html.

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

A number of other research analysts have also weighed in on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Aegis started coverage on Vanda Pharmaceuticals in a report on Wednesday, November 9th. They set a “buy” rating and a $24.00 target price for the company. Finally, Piper Jaffray Companies set a $19.00 target price on Vanda Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 24th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $20.71.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) traded up 3.276% on Friday, reaching $14.975. 746,236 shares of the company were exchanged. Vanda Pharmaceuticals has a 12-month low of $6.95 and a 12-month high of $18.00. The stock’s 50-day moving average is $14.26 and its 200 day moving average is $15.11. The firm’s market capitalization is $658.09 million.

Several hedge funds and other institutional investors have recently modified their holdings of VNDA. Acrospire Investment Management LLC raised its position in shares of Vanda Pharmaceuticals by 18.1% in the third quarter. Acrospire Investment Management LLC now owns 9,894 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 1,516 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at approximately $223,000. Capital One National Association acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at approximately $320,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Vanda Pharmaceuticals by 1.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 20,191 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 191 shares during the last quarter. Finally, Smith Asset Management Group LP acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at approximately $348,000. 95.69% of the stock is owned by institutional investors.

“Jefferies Group Research Analysts Reduce Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)” was originally posted by Web Breaking News and is owned by of Web Breaking News. If you are reading this article on another site, it was stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be viewed at http://www.webbreakingnews.com/2017/02/17/jefferies-group-research-analysts-reduce-earnings-estimates-for-vanda-pharmaceuticals-inc-vnda.html.

In other news, SVP Richard L. Gulino sold 10,900 shares of the business’s stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $15.51, for a total transaction of $169,059.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares of the company’s stock, valued at $193,875. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.45% of the stock is currently owned by insiders.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

5 Day Chart for NASDAQ:VNDA

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.